Catalent Launches OneXpress Solution to Accelerate Oral Dosage Products From Clinic to Launch
Catalent recently announced the launch of its new OneXpress service for the integrated development, scale up, and manufacturing of new oral solid dosage forms.
The OneXpress solution accelerates a program’s transition from early phase development to commercial-ready manufacturing by leveraging Catalent’s phase-appropriate scale, technologies, extensive oral dose form network, and expertise to reduce risk, complexity, and cost between phases. By eliminating the need to transition projects between multiple service providers, duplication of tasks can be avoided, API consumption can be reduced, and drug products can reach patients faster.
With a tightly integrated global network and streamlined program management, the OneXpress solution combines the expertise at Catalent’s early-phase drug development centers in Nottingham, UK, Somerset, NJ, and San Diego, CA, in the US with the proven track-record of Catalent’s oral solid commercial manufacturing facilities.
“The oral drug development path is lengthy and complex, so to maximize speed and flexibility and reduce costs, innovators need to select development partners with the expertise and capabilities that are best suited for each stage in their development cycle,” said Jeremie Trochu, Vice President, Oral and Specialty Delivery at Catalent. “Our teams have collaborated across sites to harmonize equipment, materials and protocols, to ensure accelerated and seamless scale up from first-in-human trials to commercial launch. We successfully transferred over a dozen OneXpress projects in the last year alone.”
The OneXpress solution adds to Catalent’s range of integrated offerings, including OneBio Suite, OptiForm Solution Suite, and OptiForm Total Supply, which can accelerate the development and scale up of promising compounds into successful treatments.
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.
Total Page Views: 222